🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are increasing around the world, with estimates suggesting more than 82 million instances each year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options at this time.”

Health officials are deeply concerned about the increase in drug-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Researchers anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is employed against UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This approval marks a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Worldwide Availability

As per results published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This puts it on an equal footing with the typical regimen, which involves an injection and a pill. The trial involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed hope. Having a one-pill regimen such as this is hailed as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the infection for people and to prevent the spread of untreatable gonorrhoea around the world.